(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-1.29%) $81.56
(-3.60%) $1.957
(-2.52%) $2 298.30
(-3.99%) $26.56
(-1.61%) $946.00
(0.55%) $0.938
(1.13%) $11.11
(0.57%) $0.801
(0.20%) $93.49
Live Chart Being Loaded With Signals
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics...
Stats | |
---|---|
本日の出来高 | 1.32M |
平均出来高 | 2.75M |
時価総額 | 4.58B |
EPS | HKD0 ( 2023-08-23 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -19.79 |
ATR14 | HKD0.0200 (0.42%) |
ボリューム 相関
Alphamab Oncology 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Alphamab Oncology 相関 - 通貨/商品
Alphamab Oncology 財務諸表
Annual | 2023 |
収益: | HKD218.77M |
総利益: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2023 |
収益: | HKD218.77M |
総利益: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2022 |
収益: | HKD166.85M |
総利益: | HKD122.64M (73.50 %) |
EPS: | HKD-0.350 |
FY | 2021 |
収益: | HKD146.02M |
総利益: | HKD142.99M (97.93 %) |
EPS: | HKD-0.444 |
Financial Reports:
No articles found.
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。